AZ results beat estimates on COVID-19 vaccine, Alexion and Farxiga sales

29 April 2022
astrazeneca_london_large

Soaring AstraZeneca (LSE: AZN) sales beat estimates in 2022’s first quarter, but the company’s full-year guidance remains unchanged amid an uncertain Covid-19-product sales outlook and Chinese market challenges.

Total revenue at the Anglo-Swedish drugmaker hit $11.39 billion, a 56% rise on the first quarter of 2021 and above analyst estimates of about $10.9 billion.

'2022 has started strongly for AstraZeneca'

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical